In the absence of a submission from the holder of the marketing authorisation, liraglutide (Victoza®) cannot be endorsed for use within NHS Wales for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with basal insulin, or in combination with basal insulin and oral glucose-lowering medicinal products, when these together with diet and exercise, do not provide adequate glycaemic control.